Advertisement


Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?

AACR Virtual Annual Meeting 2020 II

Advertisement

Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a response. In principle, similar benefits may result from sequential or biomarker-stratified treatments, which could be valuable in cases where toxicities may prevent full-dose combinations (Abstract 1047).



Related Videos

Gynecologic Cancers

Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins

Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract 5782).

Issues in Oncology
Leukemia

Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).

Immunotherapy

Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings

Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boost abscopal response rates. This combination therapy extends the use of radiotherapy to promote antitumor T-cell responses for both local and metastatic disease (Session ED37).

COVID-19

Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities

Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus (Session VSS06).

Colorectal Cancer

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?

Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).

Advertisement

Advertisement




Advertisement